Mineralys Therapeutics (MLYS) Scheduled to Post Quarterly Earnings on Monday

Mineralys Therapeutics (NASDAQ:MLYS) will be announcing its earnings results after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter in the prior year, the business posted ($0.31) EPS. On average, analysts expect Mineralys Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Mineralys Therapeutics Trading Down 0.8 %

NASDAQ MLYS opened at $14.04 on Friday. Mineralys Therapeutics has a 12-month low of $5.85 and a 12-month high of $16.91. The firm’s 50 day moving average is $12.90 and its 200-day moving average is $12.60.

Insider Activity at Mineralys Therapeutics

In related news, insider David Malcom Rodman sold 25,482 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $15.03, for a total value of $382,994.46. Following the completion of the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Friday, October 11th. The shares were sold at an average price of $13.57, for a total transaction of $145,972.49. Following the completion of the transaction, the chief financial officer now directly owns 236,854 shares of the company’s stock, valued at $3,214,108.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider David Malcom Rodman sold 25,482 shares of Mineralys Therapeutics stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $15.03, for a total transaction of $382,994.46. Following the transaction, the insider now directly owns 135,974 shares of the company’s stock, valued at approximately $2,043,689.22. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,510 shares of company stock valued at $735,431. 33.24% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Mineralys Therapeutics in a research note on Thursday, October 31st.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.